Share This Page
Drug Price Trends for AZILECT
✉ Email this page to a colleague
Average Pharmacy Cost for AZILECT
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| AZILECT 0.5 MG TABLET | 68546-0142-56 | 40.26172 | EACH | 2025-01-01 |
| AZILECT 1 MG TABLET | 68546-0229-56 | 40.29290 | EACH | 2025-01-01 |
| AZILECT 1 MG TABLET | 68546-0229-56 | 36.83080 | EACH | 2024-12-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Azilect (Rasagiline)
Overview of Azilect
Azilect, marketed by Teva and Lundbeck, is a selective irreversible monoamine oxidase B (MAO-B) inhibitor used in the treatment of Parkinson’s disease. It contains the pure R-isomer of rasagiline and is known for its potency, being up to 10 times more effective than selegiline without the side effect of metabolizing into amphetamine derivatives[3][4].
Market Performance and Sales
Historical Sales
Azilect has seen significant sales growth in the past. For instance, in 2014, global revenues for Azilect increased by 11% to $549 million, driven by increased prices and demand in the US and EU[3].
Current Market
As of recent analyses, the global market for Azilect is experiencing a mixed trend. In the seven major markets (France, Germany, Italy, Japan, Spain, the UK, and the US), Azilect is forecasted to decline. According to GlobalData, Azilect's sales are expected to reach $75.8 million by 2029, with a negative compound annual growth rate (CAGR) of 0.8%[1].
Regional Sales
The sales performance of Azilect varies by region:
- North America: The market is expected to see a decline, though specific CAGR figures are not provided[2].
- Europe: Sales rights in Europe were transferred back to Teva from Lundbeck in 2016 upon the availability of generics. This has impacted the sales dynamics in the region[4].
- Asia-Pacific: Similar to other regions, the Asia-Pacific market is also expected to see a decline in Azilect sales[2].
Price Analysis
Current Pricing
The cost for Azilect 0.5 mg oral tablets is approximately $1,214 for a supply of 30 tablets, depending on the pharmacy. This price is for cash-paying customers and does not include insurance plans[5].
Generic Version
A generic version of rasagiline is available, significantly reducing the cost to around $97.22 for 30 tablets. This has likely impacted the sales of the branded version of Azilect[5].
Competitive Landscape
Comparison with Safinamide
Safinamide, marketed under the brand name Xadago, has been shown to perform better than Azilect in terms of efficacy, safety, and cost-efficacy in recent pharmacoeconomic analyses. Safinamide is expected to see growth, with forecasted sales of $71.6 million by 2029, though it is still predicted to be outcompeted by opicapone (Ongentys) in the same market[1].
Comparison with Opicapone
Opicapone, a catechol-O-methyltransferase (COMT) inhibitor, has shown similar patient outcomes to safinamide but with a greater ability to facilitate levodopa dose reduction. However, Azilect remains a competitive choice due to its lower price, especially in budget-restrictive treatment scenarios[1].
Future Projections
Sales Projections
Azilect's sales are expected to decline due to several factors, including the availability of generics and the rise of competitor drugs like safinamide and opicapone. By 2029, Azilect's sales are forecasted to be $75.8 million, down from its previous highs[1].
Market Share
The global market share of Azilect is expected to decrease as other drugs gain traction. Ongentys (opicapone) is forecasted to reach sales of $118.7 million by 2029, with a CAGR of 22.9%, significantly outpacing Azilect's projected sales[1].
Key Takeaways
- Declining Sales: Azilect's sales are projected to decline due to generic competition and the rise of other adjunct therapies.
- Price Sensitivity: The availability of a generic version of rasagiline significantly reduces the cost, impacting the branded version's sales.
- Competitive Landscape: Safinamide and opicapone are emerging as strong competitors, with better efficacy and cost-efficacy profiles.
- Regional Variations: Sales performance varies by region, with declines expected in major markets.
FAQs
What is Azilect used for?
Azilect is used in the treatment of Parkinson’s disease, both as a monotherapy in early-stage patients and as an adjunctive treatment to levodopa in moderate to advanced disease[4].
How does Azilect work?
Azilect acts as a selective irreversible monoamine oxidase B (MAO-B) inhibitor, prolonging the activity of dopamine in the brain to restore normal locomotion, gait, and coordination[3][4].
Why is Azilect's sales declining?
Azilect's sales are declining due to the availability of generic versions, increased competition from other adjunct therapies like safinamide and opicapone, and a negative market trend in the seven major markets[1][2].
How does Azilect compare to safinamide?
Safinamide has been shown to perform better than Azilect in terms of efficacy, safety, and cost-efficacy. However, Azilect remains competitive due to its lower price[1].
What is the current pricing for Azilect?
The cost for Azilect 0.5 mg oral tablets is around $1,214 for a supply of 30 tablets, while the generic version costs approximately $97.22 for the same quantity[5].
Sources
- EAN 2024: safinamide surpasses rasagiline as add-on PD therapy - Pharmaceutical Technology
- Azilect - Global Market Share and Ranking, Overall Sales and ... - QY Research
- Azilect Market Report 2017 - Research and Markets - Business Wire
- Azilect - Research and Markets
- Azilect Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com
More… ↓
